Role of clobetasol propionate 0.025% topical therapy in various dermatoses

Authors

  • Vishalakshi Vishwanath Department of Dermatology, Chhatrapati Shivaji Maharaj Hospital, Kalwa, Mumbai, Maharashtra, India
  • Arvind Chaudhary Department of Dermatology, Akshara Skin Care Clinic, Deesa, Gujarat, India
  • Ankit Agarwal Department of Dermatology, N S Agrawal clinic, Bhopal, Madhya Pradesh, India
  • Bhukya Jyothi Department of Dermatology, Vasudeva Multi-speciality Hospital Karimnagar, Telangana, India
  • C. Chitharanjan Department of Dermatology, Beautiful Me Clinic, Gobichettipalayam, Erode, Tamil Nadu, India
  • Lokesh Rao Bangady Killur Department of Dermatology, Skin Care and Laser Centre, Udupi, Karnataka, India
  • M. M. Bhat Department of Dermatology, MM Bhat clinic, Kanhangad, Kerala, India
  • Nilendu Sarma Department of Dermatology, CIT Road, GD Hospital, Kolkata, India
  • Prashant K. Palwade Department of Dermatology, Satej Skin Hair Laser Center, Aurangabad, Maharashtra, India
  • Pravin Banodkar Department of Dermatology, Skin Crest Clinic, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20214097

Keywords:

Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroid

Abstract

The anti-inflammatory and vasoconstrictive properties of topical corticosteroids (TCs) contribute in providing therapeutic benefits in several skin conditions, including atopic eczema, localized vitiligo, psoriasis, and chronic hand eczema. Clobetasol propionate (CP) is the most common topical agent used for psoriasis management and demonstrates an efficacy superior to other TCs. A new CP 0.025% cream formulation has demonstrated hypoallergenic effects due to the absence of known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers. Lower CP serum levels and less hypothalamic–pituitary–adrenal axis suppression with CP 0.025% cream formulation than with CP 0.05% ensure better safety. The present case series discusses the clinical experience of using CP 0.025% cream in various dermatological conditions.

Author Biographies

Vishalakshi Vishwanath, Department of Dermatology, Chhatrapati Shivaji Maharaj Hospital, Kalwa, Mumbai, Maharashtra, India

-

Ankit Agarwal, Department of Dermatology, N S Agrawal clinic, Bhopal, Madhya Pradesh, India

-

Bhukya Jyothi, Department of Dermatology, Vasudeva Multi-speciality Hospital Karimnagar, Telangana, India

-

C. Chitharanjan, Department of Dermatology, Beautiful Me Clinic, Gobichettipalayam, Erode, Tamil Nadu, India

-

Lokesh Rao Bangady Killur, Department of Dermatology, Skin Care and Laser Centre, Udupi, Karnataka, India

-

M. M. Bhat, Department of Dermatology, MM Bhat clinic, Kanhangad, Kerala, India

-

Nilendu Sarma, Department of Dermatology, CIT Road, GD Hospital, Kolkata, India

-

Prashant K. Palwade, Department of Dermatology, Satej Skin Hair Laser Center, Aurangabad, Maharashtra, India

-

Pravin Banodkar, Department of Dermatology, Skin Crest Clinic, Mumbai, Maharashtra, India

-

References

Mehta AB, Nadkarni NJ, Patil SP. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371-8.

Das A, Panda S. Use of topical corticosteroids in dermatology: An evidence-based approach. Indian J Dermatol. 2017;62(3):237-50.

Del Rosso JQ. Topical corticosteroid therapy for psoriasis—a review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Uva L, Miguel D, Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;561018.

Zampetti A, Feliciani C, Tulli A, Amerio P. Pharmacotherapy of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses focus on clobetasol propionate. Clin Med Insights Ther. 2010;2:523-37.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®). J Cutan Med Surg. 2018;2(6):410-20.

Downloads

Published

2021-10-28

How to Cite

Vishwanath, V., Chaudhary, A., Agarwal, A., Jyothi, B., Chitharanjan, C., Bangady Killur, L. R., Bhat, M. M., Sarma, N., Palwade, P. K., & Banodkar, P. (2021). Role of clobetasol propionate 0.025% topical therapy in various dermatoses. International Journal of Research in Medical Sciences, 9(11), 3427–3433. https://doi.org/10.18203/2320-6012.ijrms20214097

Issue

Section

Case Series